SMARCB1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Jurkat cells, K562 cells, hepg2 cells, Primary antibody: P08792(SMARCB1 Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08792(SMARCB1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08792(SMARCB1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

SMARCB1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1), also known as INI1 or BAF47. is a core subunit of the SWI/SNF chromatin-remodeling complex. This complex regulates gene expression by altering chromatin structure, enabling access to transcription factors. The SMARCB1 gene is located on chromosome 22q11.2. and its encoded protein plays a critical role in controlling cell differentiation, proliferation, and apoptosis. Antibodies targeting SMARCB1 are widely used in research and diagnostics to detect the presence, localization, and expression levels of the protein in tissues or cells.

Loss of SMARCB1 protein expression, detectable via immunohistochemistry (IHC), is a hallmark of malignant rhabdoid tumors (MRTs) and epithelioid sarcomas, often caused by biallelic inactivation of the SMARCB1 gene. These antibodies also aid in diagnosing schwannomatosis-associated tumors and differentiating SMARCB1-deficient cancers from histologically similar malignancies. In research, SMARCB1 antibodies help elucidate the tumor-suppressive functions of the protein and its interplay with signaling pathways like Hedgehog and Wnt. Dysregulation of SMARCB1 is linked to aberrant SWI/SNF activity, contributing to oncogenesis. Recent studies explore its potential as a therapeutic target or biomarker in precision oncology. As a reagent, SMARCB1 antibodies require validation for specificity, given homologous proteins in the SWI/SNF family, ensuring accurate interpretation in both experimental and clinical contexts.